Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Berkshire Trims GM And Drug Stakes, Dumps Axalta, Biogen, Opens New Position In Organon

Courtesy of ZeroHedge View original post here.

Unlike last quarter, when there were a flurry of changes in the world’s most closely watched 13F, when Berkshire Hathaway liquidated almost its entire stake in Wells, sold half of its Chevron shares, added a new position in Aon PLC and trimmed its holdings in 11 positions, Warren Buffett’s just filed 13F for the quarter ended June 30 was a bit of a snoozer which had three highlights: i) the trimming of Berkshire’s holdings in GM, ii) a new position in pharma company Organon offset by the full liquidation of holdings in Biogen, and iii) the shrinkage of stakes in pharma names Merck, Bristol-Myers and Abbvie.

As shown in the table below, Buffett’s latest 13F which had a disclosed value of just over $293 billion with Apple still the largest position at 887 million shares, had no changes among the top 7 positions, and while Buffett trimmed his holdings in US Bancorp by a token 798K shares (perhaps to remain within regulatory limits) the most notable move going down the list was the 10% reduction in Berkshire’s GM stake which was cut by 7 million shares from 67 million to 60 million.

In addition to GM, a total of 8 stakes were cut in Q2 including Berkshire’s holdings in Abbvie (10% cut to 20.5 million shares), Bristol-Myers (15% cut to 26.3 million shares), as well as Merck which was cut by 48% to 9.2 million shares while liquidating its entire stake in Biogen. The company also slashed its holdings in Liberty Global, which shrank by 82%, and Chevron which saw a modest, 2% decline.

Berksire had had recently disclosed new bets on two insurance brokers, Aon and Marsh McLennan. But it took those bets in different directions during the second quarter, with the Marsh McLennan stake dropping by 20%, while the Aon position increased by 7%.

Berkshire also unveiled a new, if modest, position in Organon at 1.55 million shares accounting for $46.9 million as of Q2, while liquidating its entire position in Biogen (643K shares) as noted above, as well as a somewhat largest stake in Axalta, which was $410MM as of Q1. Finally, the conglomerate added 21% to its Kroger stake, where it now owns 61.8 million shares, up 10.8 million from last quarter.

Overall, while there were some notable moves, this was nowhere near as exciting as some of the rotation observed in recent, post-covid quarters.

The full 13F summary is below (SEC link here).


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!